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Abstract 
Rheumatoid arthritis (RA), one of the most common autoimmune disorders, is believed to be mediated via T lymphocytes and genetic 
studies have shown that it is strongly associated with HLA-DR4. The DR4 subtypes DR4Dw4, DR4Dwl4 and DR4Dwl5 represent 
increased risk factors for RA, whereas DR4Dwl0 is not associated with the disorder. Our study determines and compares the natural 
ligand motifs of these MHC class II molecules and identifies 60 natural ligands. At relative position 4 (P4), only the RA-associated DR4 
molecules allow, or even prefer, negatively charged amino acids, but do not allow those which are positively charged (Arg, Lys). In the 
case of DR4Dwl0 the preference for these amino acids is reversed. The results predict features of the putative RA-inducing peptide(s). A
remarkable specificity, almost exclusively for negative charges (Asp, Glu), is found at P9 of the DR4Dwl5 motif. This specificity can be 
ascribed to amino acid /357 of the DR/3 chain, and gives an important insight into the /357-association f another autoimmune disease, 
insulin-dependent diabetes mellitus type I. 
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1. Introduction 
Many autoimmune diseases are associated with particu- 
lar HLA class II alleles [1]. Rheumatoid arthritis, for 
example, occurs with relative high frequency in individuals 
expressing HLA-DR4. Among the DR4 alleles, DR4Dw4, 
Dwl4 and Dwl5 are associated with this disorder to a 
variable degree, whereas DR4Dwl0 is not, only weakly, or 
only in restricted populations [2-5]. Sequence differences 
among these DR4 alleles affect only few amino acids [6,7], 
most of which are located around the peptide binding 
groove. Thus, the development of rheumatoid arthritis 
might be dependent on CD4 ÷ T cells recognizing an 
epitope, or epitopes, presented by the disease-associated 
DR4 molecules but not by the non-associated ones. Such 
epitopes could be derived from normal self proteins, such 
as collagen or other joint-associated proteins, or from 
micro-organisms present locally or systemically [1,8,9]. In 
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any case, such epitopes should be central for disease 
development and - -  once identified - -  for prevention, 
diagnosis and therapy of autoimmune disease. 
One way to gain information on such potentially dis- 
ease-associated T-cell epitopes is to study carefully the 
peptide specificity of the disease-associated HLA 
molecules. The analysis of the differences in peptide fine 
specificity of disease-associated and non-associated allelic 
forms of HLA molecules hould be particularly informa- 
tive. We chose to analyse HLA-DR4Dw4, DR4Dwl4 and 
DR4Dwl5 as molecules highly associated with rheumatoid 
arthritis, and DR4Dwl0 as a closely related molecule 
which is not, or only weakly associated. 
The analysis of natural igands can be a convenient and 
successful method of obtaining information on the peptide 
specificity of MHC class II molecules [10]. Pool sequenc- 
ing of natural igand mixtures of DR molecules indicated 
allele specific motifs, which can be confirmed and refined 
by alignment of individual igands. The advantage of this 
approach is that it is possible to detect not only the 
influences of MHC peptide binding specificity but also the 
effects of antigen processing on the natural igands. On the 
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other hand, obtaining motif information solely by attempt- 
ing to align individual ligands without pool sequences has 
proved to be difficult [11-15]. The more common ap- 
proach of relying purely on peptide binding assays for 
motif determination (reviewed in Ref. [16]) has a disadvan- 
tage because it is biased towards peptide binding only, and 
does not take into account he effects of antigen process- 
ing. Furthermore, the peptide binding approach only pro- 
vides partial information since the number of peptide 
variations required to obtain complete information is usu- 
ally too high to be practical, with the exception of the 
ingenious phage peptide library approach [16-18]. 
In addition to pool sequencing and analysis of individ- 
ual natural DR4 ligands, we took advantage of the recently 
published three-dimensional structure of multipeptide/DR1 
and monopeptide/DR1 complexes [19,20]. X-ray analysis 
of such molecules indicated 5 pockets, each of which has a 
certain specificity for peptide ligand side chains. The 
specificity of the more restricted DR1 pockets (at relative 
positions 1, 4, 6 and 9) had been deduced both from 
peptide binding studies [18] as well as by ligand sequenc- 
ing analysis [10], and can be well explained by the charac- 
teristics of the corresponding pocket with regard to size, 
charge and hydrophobicity. Comparing the nature of the 
putatively corresponding pockets in the four DR4 molecules 
under study with our sequencing results gave a surpris- 
ingly clear and detailed insight into the peptide presenta- 
tion requirements of these DR4 molecules, making it pos- 
sible to predict characteristics of putative RA-epitopes. 
While this manuscript was in preparation, Hammer et al. 
[21] reported a similar conclusion based on a very different 
technique, the peptide library approach. 
In addition to those RA-related motif features, we re- 
port a peculiar specificity at P9 of the DR4DwI5 motif 
that is of importance for the functional consequences of
the f157-polymorphism and its association with IDDM. 
The motifs reported in the present paper are already 
included in recent reviews [22,23]. 
2. Materials and methods 
2.1. Cell lines 
The following homozygous EBV-transformed human 
B-cell lines were used to isolate the different HLA-DR4 
molecules: LRM (A2; B44; DRBI*0401; DQAI*03; 
DQBI*0301; DP4), A1 10 (A26; B38; DRBI*0402; 
DQAI* 03; DQBI* 0302; DP4), MFF (All,31; B60; Bw6; 
Cw3; DRBI*0404), WTA (DRBI*0405; DQAI*03; 
DQBI*0401). PCR typing was performed by J. Mytili- 
neos. Serological and cellular typing results are from the 
HLA defined collection, European Collection of Animal 
Cell Cultures (ECACC), Salisbury; and from G. Pawelec. 
Due to its haplotype family, HLA-DR4 is tightly linked to 
HLA-DR53 (DRB4* 0101). Since it is known that DRB1- 
genes are transcribed five to ten times higher than the 
respective DRB4-genes [24], the peptide contribution of 
DR53 molecules, expected to co-precipitate with DR4 
molecules in our experiments, hould be small or negligi- 
ble. 
2.2. Antibodies 
Immunoprecipitations were performed with L243 anti- 
bodies [25] specific for HLA-DR. Hybridomas were grown 
in roller culture. Supernatant was precipitated with ammo- 
nium sulfate and the antibodies were further purified on a 
Protein A-Sepharose column (Pharmacia, Freiburg, Ger- 
many). 
2.3. Cell culture 
For bulk culture, cells were grown at 37°C in 2 1 glass 
roller bottles (Schott Duran, Frankfurt/Main, Germany) 
with up to 1 1 Dulbecco's modified Eagle's medium 
supplemented with 5% fetal calf serum (FCS), 5% new- 
born calf serum (NCS), glutamine and 2-mercaptoethanol. 
Cells were split every three to four days. For harvest, 
(typically 24-28 1) cell suspensions were pelleted with a 
continuous flow rotor (Beckman, Munich, Germany). Cell 
pellets were either used directly for peptide extraction or 
stored at - 70°C. 
2.4. MHC precipitation and peptide extraction 
This was done as described [26]. Briefly, pellets (20-40 
ml) were lysed in 1% (v/v) NP-40, lmM PMSF, 0.02% 
(w/v) pepstatin, 0.02% (w/v) leupeptin and 0.02% (w/v) 
aprotinin (Boehringer Mannheim, Germany). The lysate 
was ultracentrifuged for 65 min at 86,000 g. The super- 
natant was passed at least twice over Sepharose beads 
(Pharmacia, Freiburg, Germany) coupled with glycine and 
then over Sepharose beads coupled with L243 antibodies. 
Peptides were acid-released from the loaded beads by 
treatment with 0. 1% (v/v) trifluoroacetic acid (TFA). 
Glycine beads were treated the same way, using extracted 
material as a control for molecules ticking nonspecifically 
to beads (see Fig. 1). In order to remove antibody molecules 
and HLA-DR a- and /3-chains from the peptides, the solu- 
tion was passed through ultrafiltration membranes 
(Centricon 10, Amicon, Witten) of 10 kDa exclusion size. 
The filtrate was separated on a reversed-phase HPLC 
column (/zRPC C2/C18; 2.1 X 100 ram; Pharmacia), us- 
ing a SMART system (Pharmacia). Eluent A was 0.1% 
(v/v) TFA in water, Eluent B was 0.081% (v/v) TFA in 
80% acetonitrile/water. All eluents used were of HPLC 
grade (Riedel de Haen, Frankfurt, Germany). The gradient 
used was the same as previously described [10]. Peptide 
fractions were pooled, whereby dominant single peaks 
were omitted. Pools and dominant single peaks were se- 
quenced separately. 
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2.5. Peptide analysis 
Pools and single peaks were sequenced by Edman 
degradation on a pulsed-liquid protein sequencer 476A 
with on-line PTH-amino acid analysis (Applied Biosys- 
terns, Weiterstadt, Germany) as described [27]. Cys was 
not modified, and therefore not detectable. 
2.6. Interpretation of pool sequencing 
In the raw data tables, amino acids are ordered accord- 
ing to their hydropathy [28], which facilitates perception of 
certain physico-chemical groups clustering in cycles of 
Edman degradation. Two arbitrary levels of significance 
were used for evaluation of data. An increase in the 
amount of a given PTH amino acid at a given cycle of 
more than 50% as compared to the previous cycle, is 
considered highly significant as indicated by bold typing. 
An increase of less than 50% is considered to reflect a 
significant signal and is indicated by italic typing the 
respective numbers. In some instances, a decrease smaller 
than the lag effect usually found for a given amino acid is 
taken as an indication that some of the peptides in the pool 
have this amino acid. Such values are also italicised. 
3. Results 
3.1. Analysis of DR4Dw4 eluted peptides 
Large batches of the EBV-transformed B-cell line LRM 
(DRBI*0401) were grown in liquid cell culture. DR 
molecules were immunoprecipitated using L243 antibod- 
ies. A potential complication here is the co-expression of
HLA-DR4 linked HLA-DR53 genes. However, since DR53 
expression is usually much lower than that of DR4, peptide 
contribution of DR53 in our experiments should be smaU 
or negligible. (See also Section 2). DR-associated peptides 
were extracted by TFA-treatment and separated by HPLC 
(Fig. 1A). Material eluting in large distinct peaks was 
collected into individual fractions and sequenced by Ed- 
man degradation. The remaining fractions (as indicated in 
OD 
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Fig. 1. HPLC separation of DR4 ligands. Peptides dissociated from immunoprecipitated DR4Dw4 (a), DR4Dwl0 (b), DR4Dwl4 (c) and DR4Dwl5 (d) 
molecules were separated by reversed phase HPLC. The arrows indicate peaks collected and sequenced individually. Fraction numbers of these peaks are 
also indicated in Tables 2, 4, 6, and 8. The horizontal bars indicate the fractions pooled for pool sequencing. Numbered peaks, however, were omitted from 
these pools. The lower curve shows the extinction of the glycine control at 214 nm. 
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Fig. IA) were pooled and sequenced as such (Table 1). 
The pool sequencing data appeared similar, in principle, to 
that of other class II ligands [10]. Thus, a Pro signal was 
prominent at cycle 2 (probably as a result of enzymatic 
activity during processing) [10] and a number of hydropho- 
bic amino acids were found to be clustered over about 
three cycles. Such clusters reflect the fixed anchor posi- 
tions used by ligands to interact with the peptide-accom- 
modating roove of class II molecules. The occurrence in 
clusters rather than at fixed positions in the pool sequenc- 
ing data is due to the variable distance between the peptide 
N-terminus and the first anchor in the different ligands. 
For example, cycles 3, 4 and 5 show strong signals for a 
number of hydrophobic or aromatic residues, especially 
Tyr, Phe and Met (Table 1). Another cluster is seen at 
positions 6, 7 and 8, this time dominated by Val and Ala, 
but lacking Tyr. The first cluster centered at cycle 4 
represents he first anchor of ligands (set at relative posi- 
tion 1), and the second cluster centered at cycle 7, the 
second one. 
Such analysis led to a basic DR4Dw4-motif with hy- 
drophobic anchors at relative position 1 (corresponding to
cycle 4) and relative position 4 (reflecting cycle 7) (Table 
2). The other details of the motif shown in Table 2 are 
derived from a careful comparison of pool sequencing 
results, individual igands, and DR1 crystal structure (see 
discussion). A number of individual ligands, corresponding 
to the larger peaks in Fig. 1A, could be sequenced directly 
(Table 2). Some of the most prominent DR4Dw4 ligands 
are from the HLA-A2 molecule co-expressed by LRM 
cells. The high abundance of A2-derived ligands is well 
illustrated by the fact that the corresponding sequences can 
be followed even in the pool sequencing data. For exam- 
ple, the partial sequence QFVRFDSDA can be easily 
followed from cycle 5 through 13 (Table 1), standing out 
as unclustered signals. All individual DR4Dw4 ligands 
sequenced, including several reported by Chicz et al. [14], 
are shown in alignment to the motif. Details of alignment, 
in addition to the hydrophobic anchors at relative positions 
P1 and P4, such as the occurrence of exceptional hy- 
drophilic residues at P4 and the occupancy of P6, P7 and 
P9 are covered in Section 4. 
3.2. DR4DwlO 
DR-associated peptides were isolated from large batches 
of AI-10 cells, being homozygous for DR4Dwl0 
(DRB1 * 0402), and separated by HPLC (Fig. 1B). Material 
eluting in large, distinct peaks was collected and se- 
quenced separately. All other fractions eluting between 
28.0-58.5 min elution time were sequenced as a pool 
(Table 3). As with all other class II ligand pools we have 
sequenced so far, a sharp Pro signal at cycle 2 is evident 
[10,29]. This signal is so well reproducible, irrespective of 
the class II molecule considered, that it is used as a marker 
for the quality of the respective peptide isolations. A 
clustering of hydrophobic amino acids, especially Leu and 
Ile, is visible for cycles 3, 4 and 5. Significant clustering of 
hydrophilic residues at cycles 2 and 3 is also evident, as 
previously found for other class II ligand pool sequences 
[10]. Less pronounced is a cluster of hydrophobic residues 
around cycle 7, consisting of Met, Leu and Phe. These data 
lead to a basic DR4Dwl0 ligand motif with a hydrophobic 
anchor at a relative position P1, reflecting the cluster at 
cycles 3, 4 and 5. A second anchor is then at P4, with 
preference for hydrophobic residues (Table 4). Twenty-one 
individual ligands, derived from 10 different proteins, were 
sequenced. The most abundant ligands are from HLA-B38, 
which is co-expressed in AI-10 cells. One peptide is from 
invariant chain. About half of the peptides can be well 
aligned to the basic motif with hydrophobic residues at P1 
and P4, while the other half has an aliphatic residue to be 
aligned with PI but no corresponding hydrophobic residue 
at P4. This indicates that P4 must allow other than hy- 
drophobic residues as well. At first glance, the further 
positions within the ligands do not present hemselves as 
clear anchors. However, a careful analysis of aligned 
ligands, pool sequencing results, and pocket structure re- 
veals degenerate but still distinct specificities at P6, P7 and 
P9 (see discussion). 
Table 6 
HLA-DR4Dwl4 motif and ligands 
Relative position Source Fraction 
1 2 3 4 5 6 7 8 9 
Anchor or V,I F,Y,W N,T polar, polar, 
preferred L,M I,L S,Q charged, aliphatic, 
residues V,M,A R aliphatic K 
D,E 
no R,K 
1 2 3 4 5 6 7 8 9 
GSHS M R Y F H T A M S RPGRGE HLA-B60 (1-?) 34, 35, 36, 48 
SHS M R Y F H T A M S RPGRGE HLA-B60 (2-?) 34, 35, 36, 48 
YDNS L K I I S N A S C TTN GAPDH (139-154) 40 
a Deferred from pool sequence, individual ligands, and pocket structure. GAPDH, glycerine aldehyde 3-phosphate dehydrogenase. 
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3.3. DR4Dwl4 3.4. DR4Dwl5 
DR ligands were isolated from DR4Dwl4 homozygous 
MFF cells (DRB 1 * 0404) (Fig. 1C). Pool sequencing again 
gave a very strong stand-alone signal for Pro at cycle 2 
(Table 5). The sequences of a pair of individual igands, 
corresponding to the N-terminus of HLA-B60 
(GSHSMRYF. . . )  and its N-terminal truncation 
(SHSMRYF...) can be followed through the pool sequence. 
This results in doublets of the respective residues at con- 
secutive cycles. See, for example, Arg signals at cycles 5 
and 6, Tyr at 6 and 7 and Phe at 7 and 8. In addition to 
these dominant sequences, everal significant clusters can 
be observed. The most significant one is at cycles 4 and 5, 
both of which show very strong signals for the aliphatic 
residues lie, Leu and Val. A second cluster of hydrophobic 
residues, of lesser intensity, is at cycles 7 and 8 for Met, 
Ile and Ala. In addition, the Phe signals at 7 and 8 are 
stronger than would be expected, if derived only from the 
two dominant B60 peptides. Thus, Phe is probably part of 
this cluster. Cycles 9 and 10 indicate a cluster for the 
hydrophilic residue Asn and potentially Thr (belonging to 
the two dominant B60 peptides). Further details on the 
considerations leading to the motif shown in Table 6 are in 
Section 4. 
Source of peptides was the cell line WTA 
(DRBI* 0405). Pool sequencing of HPLC-purified pep- 
tides (Fig. 1D) again gave a strong and sharp signal for Pro 
at cycle 2, and a cluster of hydrophilic residues at cycles 2 
and 3 (Table 7). A very significant cluster of the aromatic 
residues Tyr and Phe is evident in cycles 3, 4 and 5, 
accompanied by weak signals for the aliphatic residues 
Met and lie. A second cluster of aliphatic residues, occur- 
ring at cycles 6, 7 and 8, is dominated by Val, Ile and Ala 
but lacks the aromatic residues Tyr and Phe. Other clusters 
are at cycles 9 and 10 for Asn and other hydrophilic 
residues, and very significantly, at 12 and 13 for Asp, 
accompanied by other hydrophilic residues. 
A basic motif indicated by this pattern of clusters is as 
follows (Table 8). P1 (represented by the cluster at cycles 
3, 4 and 5) is an anchor dominated by the aromatic 
residues Tyr and Phe, but which also allows aliphatic 
residues. P4 (corresponding to the cluster at cycles 6, 7 
and 8) is an anchor with preference for aliphatic residues. 
P6 shows a preference for Asn and other hydrophilic 
residues, whereas P9 is an anchor dominated by the nega- 
tively charged Asp. Seventeen i dividual peptides, derived 
from 9 different proteins, were sequenced (Table 8). All 
Table 8 
HLA-DR4Dwl5 motif and ligands 
Relative position 
1 2 3 4 5 6 7 8 9 
Source Fraction 
anchor or F, Y, V, I, L, N, S polar, 
preferred W M T, Q charged, 
residues V, I D, E K, D aliphatic 
L ,M 
1 2 3 4 5 6 7 8 9 
YPTQRAR Y Q W V R C N P D 
QRAR Y Q W V R C N P D 
RAR Y Q W V R C N P D 
KPPQ Y I A V H V V P D 
FRE F K L S K V W R D 
FRE F K L S K V W R D 
RE F K L S K V W R D 
RE F K L S K V W R D 
VEPDH Y V V V O A Q R D 
EPDH Y V V V O A Q R D 
THY Y A V A V V K K D 
KELK I D I I P N P Q E 
YLL Y Y T E F T P T E 
LL Y Y T E F T P T E 
CAIHAKR V T I M P K D I Q 
APNT F K T L D S W R D 
VADK I Q L I N N M L D 
D ,E ,Q  
SNS PGSG (1-19) 19 
SNS PGSG (4-19) 19 
SNS PGSG (5-19) 19 
Q MIF (32-45) 28, 44 
QH Transferrin receptor (173-186) 
Q Transferrin receptor (173-185) 
QH Transferrin receptor (174-186) 28 
Q Transferrin receptor (174-185) 31 
A Transferrin receptor (397-41 l) 33 
A Transferrin receptor (398-411) 32 
TDFK similar to transferrin 
R Hsp 90-beta (68-81) 33 
KD /32-microglobulin (83-96) 54 
KDEY /32-microglobulin (84-98) 
LA . . .  Histone H3 (110-?) 36 
ras-related protein RAB-7 (rat) 36 
(86-98) 
Phosphoglycerate kinase 55, 46 
(216-228) 
Deferred from pool sequence, individual ligands, and pocket structure. PGSG, secretory granule proteoglycan core protein; MIF, macrophage migration 
inhibitory factor. Three peptide sequences (KVHGSLARAGKVRGQTPKVA . . . .  SSHKTFRIKRFLAKKQKQNR . . . .  GKFMKPGKVVLVLAGRYS... ) 
of ribosomal proteins were not aligned because their ligand nature appears to be questionable for several reasons: (i) they represent the N-terminal parts of 
the respective protein, (ii) the C-terminal residues could not be characterised due to their unusual length of more than 20 residues, (iii) they have been 
found frequently in ligand extractions of different class II proteins. 
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can be aligned very well to the basic motif, especially with 
respect o P1, P4 and P9. Details of the motif indicated in 
Table 8 are discussed below. 
4. Discussion 
We have analyzed natural peptide ligands of four closely 
related DR4 molecules which differ in their association 
with rheumatoid arthritis. Clustering of amino acid signals 
in pool sequences makes it possible to interpret basic 
allele-specific motifs consisting of at least two anchors at 
relative position P1 and P4 of peptide ligands. Individual 
peptides could be well aligned to these motifs. 
The structural information of a monopeptidic DR1 crys- 
tal indicated 5 pockets in the DR1 groove, accommodating 
the side chains of the residues at relative positions P1, P4, 
P6, P7 and P9 of the peptide [19,20]. The closely related 
DR4 molecules are expected to have a similar pocket 
arrangement but with variance of individual pocket speci- 
ficities. The pool sequences can be interpreted in the light 
of the predicted pocket structures (Table 9). P1 of ligands 
is reflected by a cluster of hydrophobic residues tretching 
around sequencing cycles 3 to 5, as known from previous 
analysis of DR1 ligands [10]. The residues contributing to 
the P1 pocket in the DR1/influenza peptide crystal are 
identical in DR4Dw4 and DR4Dwl5. Indeed, occupancy 
of P1 in the respective ligand mixtures is very similar to 
the PI specificity of DR1 ligands: hydrophobic residues 
with a preference for aromatic amino acids (Table 9). For 
DR4Dw4, this P1 specificity has also been detected by 
peptide binding assays [17,30-32]. In contrast, DR4Dwl0 
and DR4Dwl4, differing from DR1 (/386Gly) at only one 
position in the PI pocket (f186Val) show a different P1 
specificity: hydrophobic residues with preference for 
aliphatic amino acids. This difference in pocket specificity 
imposed might be explained by a reduction of the P1 
pocket volume by the larger/3 86Val side chain as opposed 
to the /386Gly hydrogen atom in DR1 [19,20,29,33,34]. 
The pocket for the P4 side chain (pocket No. 2 [20]) is, 
in the case of DR1, more degenerate in its specificity as 
compared to the PI pocket. P4 of DR1 ligands can be 
occupied not only by aliphatic residues but also by polar 
Ash or Gin [10,18-20]. DR/3 chain residues polymorphic 
among DR1 and the four DR4 molecules considered here 
and contributing to the P4 pockets are /313, f170 and 
/3 71. Polymorphism of this pocket is indeed reflected in 
the P4 specificity of these 5 molecules, although all of 
them show a preference for hydrophobic residues at P4. 
The P4 pocket has one more positive charge (/313His) in 
DR4Dw4, Dwl4 and Dwl5 as compared to the P4 pocket 
of DR1 (fl l3Phe). Thus, one should expect negative 
charges to be allowed at P4 of ligands, and this should be 
reflected at cycles 7 and 8 of the pool sequences. Indeed, 
for DR4Dw4 (Table 1) the absolute amounts of Asp and 
Glu were generally higher than those of Arg and Lys, Asp 
and Glu signals increased at both cycles 7 and 8, and the 
significant Arg signal at cycle 8 is isolated (not clustered), 
indicating that it belongs to an individual dominant pep- 
tide. Indeed, this Arg signal can be allocated to represent 
P3 (absolute position 8) of some of the dominant DR4Dw4 
ligands derived from HLA-A2. Even with the isolated Arg 
signal included, the ratio of cumulated Asp and Glu values 
versus Arg and Lys in cycles 7 and 8 of the pool sequence 
is greater than 1 (1.23) and His signals are weak and 
decreasing. This observation gains significance if the cal- 
culation is repeated for DR4Dwl0. Here, the P4 pocket 
has two additional negative charges (fl70Asp and 
/371Glu) as compared to Dw4, and thus, positive but not 
negative charges are expected at P4 of ligands. Inspection 
of Asp/Glu vs. Arg/Lys signals at cycles 7 and 8 of pool 
sequence (Table 3) indeed indicates much higher signals of 
the latter, with a ratio of cumulative Asp/Glu signals vs. 
Arg/Lys of 0.43. In addition, His signals are very signifi- 
cant and increasing. Thus, the P4 pocket of DR4Dwl0 
appears to allow positively but disfavours negatively 
charged residues at P4 of ligands. In contrast, the corre- 
sponding pocket of DR4Dw4 allows negative charges but 
should not allow positive ones at P4 of ligands. Indeed, of 
the 24 Dw4 ligands aligned in Table 2, five have Asp or 
Glu at P4, and none has a positive charge. Likewise, 
peptide binding experiments indicated that positive charges 
at P4 of peptides inhibit binding to DR4Dw4 [31]. The 
results of two recent papers by Hammer et al. [21,35] 
based on synthetic peptide libraries are in accordance with 
our results with respect o the P4 specificity. Hammer et 
al. found Lys and Arg at P4 to be favoured in binding to 
DRBI*0402 as compared to DRBI*0401, whereas 
DRBI*0404 was similar in this respect o DRBI*0401, 
which is in perfect agreement with our findings. For Asp 
and Glu at the same position, Hammer et al. found that the 
peptides bound weaker both to DRB 1 * 0402 (200- to 500- 
fold) and DRBI* 0404 (20- to 50-fold), as compared to 
DRBI* 0401. Our results fit well with those findings; the 
relative preference of hydrophobic residues at P4 of 
DRB 1" 0404 over DRB 1" 0401 associated peptides might 
be interpreted as a consequence of the Lys/Arg substitu- 
tion at position 71 from DRBI* 0401 to DRBI* 0404. For 
DR4Dwl4 and Dwl5, the charge distribution in the P4 
pocket is similar to that of DR4Dw4. Indeed, the Asp/Glu 
versus Arg/Lys ratio at cycles 7 and 8 of the Dwl4 pool 
sequence is similar as for Dw4 (1.29), so that the P4 
specificities of DR4Dw4 and DR4DwI4 are very similar 
(Table 9). For DR4Dwl5, however, the levels of Asp/Glu 
and Arg/Lys at cycles 7 and 8 are not much different. 
Two of the 17 individual igands aligned in Table 8 carry 
Glu at P4, so that negatively charged residues appear to be 
tolerated at P4. 
Two important points emerge from this consideration of
P4 specificities of the different DR4 molecules: i) without 
the X-ray crystallography data on pocket structure, the 
detailed evaluation of DR4 ligand pool sequences would 
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not have been possible, and ii) the P4 specificity appears to 
be one major feature discriminating the different DR4 
molecules, confirming P4 as an allele-specific anchor [16]. 
The P6 pocket of DR1 (pocket No. 3 [20]) prefers mall 
residues [10,16,18,20]. All 4 DR4 molecules considered 
here differ from DR1 in two /3-chain residues contributing 
to the P6 pocket (/3 11Val and /3 13His). Indeed, all 4 DR4 
molecules have a similar specificity here which is different 
from P6 of the DR1 molecule. P6 of these DR4 molecules 
accommodate polar residues, especially Asn, Gin, Ser, Thr 
as well as to a limited extent charged ones. The latter 
amino acids have not been reported previously. Hammer et 
al. [17,30] found that positive amino acids are disfavoured 
at P6. In addition to this, Sette et al. [31] found negatively 
charged amino acids to have a negative ffect on binding. 
Both groups solely considered positive or negative ffects 
of certain substitutions in synthetic or recombinant pep- 
tides on binding to DR4Dw4 molecules without looking at 
constraints of processing. The latter constraint might heav- 
ily influence the natural peptide repertoire presented by 
class 1I molecules. The 66 individual DR4 ligands aligned 
in Tables 2 and 4, 6 and 8 indeed confirm the rather 
degenerate nature of P6 in that, in addition to polar and 
charged residues, aliphatic residues are also found, which 
this time is in agreement with the results by Sette et al. 
[31]. 
The P7 pocket (pocket No. 4 [20]) is even more degen- 
erate, at least for DR1, where no specificity could be 
detected [10,16,18] as well as for DR4Dw4, Dwl4 and 
Dwl5. Since DR4Dwl0, however, has replaced the basic 
/371 (Arg or Lys) residue of DRI and the other DR4 
molecules by a negatively charged /3 71Glu, cycles 10 and 
11 of the pool sequence as well as P7 of the 21 individual 
Dwl0 ligands aligned in Table 4 were inspected. The 
expected preference for positively charged residues is indi- 
cated by the cumulative ratio of 0.47 for Asp/Glu values 
versus Arg/Lys at cycles 10 and 11 of for Dwl0 (as 
opposed to 2.41 for Dw4, 2.54 for Dwl4 and 1.29 for 
Dwl5), and P7 of the aligned ligands was positively 
charged in 12 peptides (belonging to 5 nested sets) out of 
the 21 Dwl0 ligands, whereas a negative charge was found 
only once. Thus, P7 is rather nonspecific n DR1, DR4Dw4, 
DR4Dwl4 or DR4Dwl5 allowing polar, charged and 
aliphatic residues, whereas P7 of DR4Dwl0 has a prefer- 
ence for positively charged residues and disfavours nega- 
tive charges. 
The pocket for P9 side chains (Pocket No. 5 [20]) of 
DR1 has a preference for aliphatic residues while allowing 
aromatic and some polar residues as well [10,16,18,20]. 
The P9 pockets of DR4Dw4, Dwl0 and Dwl4 differ from 
that of DR1 at one residue, /39Glu instead of/39Trp. This 
change is obviously responsible for the lack of a signifi- 
cant clustering of hydrophobic residues at P9, that is cycles 
12 through 14 of pool sequences. Instead, signals for polar, 
aliphatic and positively charged residues are found here, as 
well as at P9 of aligned ligands. Thus, P9 of DR4Dw4, 
Dwl0 and Dwl4 is a rather degenerate anchor, more 
characterized by residues disfavoured - negatively charged 
residues and aromatic ones - rather than preferred. P9 
would not have been assigned as an anchor of DR4Dw4, 
Dwl0 and Dwl4 based on ligand sequencing alone, if the 
structure analysis of DR1 had not predicted such an an- 
chor. 
In contrast, P9 of DR4Dwl5 is different. The P9 pocket 
of this molecule differs from those of the other three DR4 
molecules (/357Asp) in one residue, /357Ser. Thus, the P9 
pocket of DR4Dwl5 has one negative charge less as 
compared to the P9 pockets of DR1, DR4Dw4, Dwl0 and 
Dwl4. The cluster of amino acids at cycles 12 to 14 
reflects this difference very clearly: it shows a striking 
preference for the negatively charged residues Asp and 
Glu (Table 7). Indeed, almost all of the DR4Dwl5 ligands 
aligned in Table 8 have Asp or Glu at P9. Thus, P9 
appears to be an anchor for negatively charged residues or, 
to a lesser extent, polar residues, as indicated by the pool 
sequence cluster and P9 of individual ligands. This implies 
that the P9 pocket of DR4Dwl5 must carry a positive 
countercharge; this is probably provided by a 76Arg. Since 
a 76Arg is conserved among the DR molecules considered, 
it is assumed that the positive charge at a 76Arg is neutral- 
ized by /357Asp in DR1, DR4Dw4, Dwl0 and Dwl4 
molecules. 
Comparing these detailed peptide motifs, it becomes 
apparent hat each of the 5 pockets can contribute to 
allele-specific peptide binding. P1 is the least variable one, 
limited to the Gly/Val polymorphism at /3 86 of all DR/3 
chains and determining the preference of either aromatic or 
aliphatic residues at PI of ligands. In contrast, specificity 
of the P4 pocket, appears to be highly variable, as indi- 
cated by our present data on DR4 subtypes as well as in 
previous data on DR1, DR3 and other molecules 
[10,14,16-18,20,30,36]. P6 is rather similar among the 
DR4 subtypes tudied here, which is well explained by 
identical P6 pockets, whereas P6 pocket composition as 
well as specificity is different in DR1. Specificity of the P7 
pocket is rather degenerate; only for DR4Dwl0 is it more 
pronounced, in that positive or polar residues at P7 of 
ligands are preferred. P9 specificity is degenerate in 
DR4Dw4, Dwl0 and Dwl4 but not in DR4Dwl5 and 
DR1, and has either a pronounced preference for nega- 
tively charged and polar residues (DR4Dwl5) or a prefer- 
ence for hydrophobic residues (DR1). 
As indicated above, the combined information gathered 
from pool sequencing, individual igand sequencing, and 
crystallographic analysis is a powerful tool for determining 
allele-specific peptide motifs of class II molecules. The 
polymorphism of DR/3 residues contributing to pockets in 
one particular DR1/peptide complex can well explain the 
polymorphic specificities of several other DR molecules, 
including the DR4 subtypes tudied here. However, since 
the contribution of individual DR/3 positions to pockets 
might be different in different DR molecules, interpretation 
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of pocket structures in other DR molecules hould be done 
with caution [20]. Indeed, it appears that DR molecules 
with the same composition of pocket residues, as defined 
for the DR1/influenza peptide complex, may have differ- 
ent pocket specificities. For example, P4-pocket residues 
of DR4Dwl4 and Dwl5 are identical whereas the pocket 
specificity is different: P4 of Dwl4 ligands shows a prefer- 
ence for aromatic rather than aliphatic residues and does 
not tolerate positively charged residues, whereas Dwl5 
prefers aliphatic residues, and shows much less discrimina- 
tion of charged residues. Thus, pocket specificity cannot 
be predicted to the point by the DR/3 sequence alone, 
since DR/3 residues other than those used in the DR1/in- 
fluenza peptide complex might contribute to pocket struc- 
ture in different DR molecules. 
The central question of this paper is the relation be- 
tween peptide specificity and disease association of DR4 
molecules. Although there is some disagreement among 
authors concerning the levels of association between 
rheumatoid arthritis (RA) and DR expression reported for 
different populations, there is still a certain consensus. 
DR4Dw4 and Dwl4 are strongly associated with RA as is 
DR4Dw 15, but, in this case, only in the Japanese popula- 
tion, DR1 intermediately, and DR4Dwl0 is not at all or 
weakly associated [1-5,37]. Thus, it should be of interest 
to inspect he peptide motifs of the different DR4 molecules 
for features correlating to the levels of disease association. 
Most striking in this respect are the different preferences 
for charged residues at P4 of ligands. Both strongly RA-as- 
sociated Dw4 and Dwl4 do not tolerate positive charges at 
P4, whereas they have a moderate preference for nega- 
tively charged residues. The opposite is found for the least 
RA-associated DR4 molecule, Dwl0; here P4 does not 
tolerate Asp or Glu, but has a preference for positively 
charged residues. For DR4Dwl5 as well as for DR1, the 
charge discriminations at P4 are much less pronounced. 
Another difference in charge preference is at P7; whereas 
the strongly or intermediately RA-associated DR1, 
DR4Dw4, Dwl4 and Dwl5 molecules are rather degener- 
ate in P7 specificity, the non-associated DR4Dwl0 shows 
a preference for positive charges at P7 of ligands. On the 
other hand, the specificity of P1 and P6 does not seem to 
show any correlation with RA association, at least within 
the DR4 groups considered here. The /3 86 Val/Gly poly- 
morphism, influencing P1 specificity, does not seem to be 
important here; it has been indicated however, that this 
difference is correlated with RA association in another 
context [2]. When the most strongly RA-associated DR4 
molecules, DR4Dw4 in the Caucasoid population and 
DR4Dwl5 in the Japanese population are compared, it 
strikes the eye that they differ in P9. DR4Dwl5 shows a 
prominent specificity for negatively charged amino acids, 
whereas DR4Dw4 shows a preference for small hydropho- 
bic and polar amino acids, respectively. This might be 
indicative of an epitope difference dependent on the re- 
gional occurrence of the possible disease-inducing a ents 
analogous to the difference in protective DR alleles with 
respect o different malaria-causing Plasmodium strains 
[38]. As a consequence of these different P9 specificities, a 
negatively charged amino acid should be included at P9 if 
a common RA-inducing peptide motif in the Japanese 
population is to be postulated. 
Table 10 
Candidates for RA inducing peptides? 
a. Suspected features L X X D X T D X X 
of RA-inducing I E S E 
peptides V N 
M Q 
b. Fitting stretches 
within antigens 
possibly involved 
in RA 
Known B cell or T cell antigen 
Mycobacterial 19kD lipoprotein 
antigen precursor a 88-96 
Mycobacterial HSP 65 b,c 
Calreticulin/Ro/SS-A d 
Collagen a l(II)precursor e 
V L T D G N P P E 
83-91 V A G D G T T T A 
173-181 * I T V E E S N T F 
183-191 L Q L E L T E G M 
323-331 V T K D E T T I V 
97-105 V K H E Q N I D C 
176-184 V R P D N T Y E V 
184-192 V K I D N S Q V E 
1312-1320 L S T E O S Q N I 
1352-1360 I R A E G N S R F 
* Reported as T cell epitope by Danieli et al. [41]. 
a Tan et al. [9]. 
b Danieli et al. [41]. 
Quayle et al. [42]; Routsias et al. [43]. 
e Worthington et al. [44]. 
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Interestingly, DR4Dwl5 lacks an aspartate at position 
57 of its /3-chain, as does HLA-DQ8 which is strongly 
associated with Insulin-dependent Diabetes (Type I) and 
its murine homolog H-2A g7 of the NOD mouse. Peptides 
bound to the latter two MHC class II molecules have been 
studied [39,40]; although apreference for a negative charge 
at P9 has been noted, such an extraordinary specificity as 
for P9 in DR4Dwl5 has not been found. 
Under the assumption that RA is caused by a T-cell 
response against a peptide presented by the RA-associated 
DR molecules but not by the non-associated ones, one can 
now start to think about the features uch a hypothetical 
peptide should have. Or, in other words, how should a 
peptide look that is presented well by DR4Dw4, Dwl4 and 
DR4Dwl5, moderately by DR1, and not at all by 
DR4Dwl0 molecules? Based on the above considerations 
and the data summarized in Table 9, the hypothetical 
RA-inducing peptide should look as follows: P1 is hy- 
drophobic (aliphatic or aromatic), P4 is Asp or Glu. P6 is 
Ser or Thr (common for P6 residues of DR1 and DR4 
ligands). P7 is not specified but more likely is occupied by 
an Asp or Glu rather than another residue. P9 is not 
specified for the Caucasoid population; for the Japanese, it 
would be Asp or Glu. Thus, a sequence like LXXEX- 
SEXX (LXXEXSEXE for Japan) would be the core of 
such a speculative RA inducing peptide, which, as a 
natural DR ligand, would include 3 or 4 flanking residues 
at either side of the core sequence. The likely source of 
such a peptide would be a self protein expressed in the 
joint, such as collagen, or a bacterial antigen crossreactive 
to a self protein of the joint. For some of the antigens that 
have been reported to be possibly involved in RA [9,41- 
44], we performed an epitope search based on the above 
hypothesis (Table 10). The result indicated a number of 
fitting stretches within these proteins, including part of a T 
cell epitope of mycobacterial HSP 65 reported by Danieli 
et al. [41]. We are aware that our exercise here is highly 
speculative but we think it provides a useful basis for the 
design of future experiments, the aim of which is to 
identify peptides inducing RA as well as other autoim- 
mune diseases, and to base new strategies for prevention 
and therapy on this information. 
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